Knowledge Hub

Global Pharmerging Market To Grow At A CAGR Of 12.88% During The Period 2017-2021

Press Release   •   Jan 31, 2017 07:22 EST has recently announced the addition of a market study “ Global Pharmerging Markets 2017-2021 ”, is a comparative analysis of the global market.

About Pharmerging

The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Technavios analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography:

Tier 1

Tier 2

Tier 3

Technavio's report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors






Download The sample Copy Of This Report:

Other prominent vendors

Abbott Laboratories


Alexion Pharmaceuticals




Astellas Pharma




Boehringer Ingelheim

Bristol-Myers Squibb


CSL Behring

Daiichi Sankyo

Dainippon Sumitomo Pharma


Eli Lilly

Endo Health Pharmaceuticals

F. Hoffmann-La Roche




H. Lundbeck


Johnson & Johnson

Kyowa Hakko Kirin

Mallinckrodt Pharmaceuticals


Mitsubishi Tanabe Pharma


Novo Nordisk



STADA Arzneimittel

Sun Pharmaceutical

Takeda Pharma

Teva Pharmaceutical Industries


Valeant Pharmaceuticals

Market driver

Limitations in developed economies fuels demand in emerging economies

For a full, detailed list, view our report

Market challenge

Stringent price control and generic -centric usage lead to value erosion

For a full, detailed list, view our report

Market trend

Potential of new countries in emerging markets

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2021 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Table Of Content

PART 01: Executive summary

PART 02: Scope of the report

Market overview

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights


PART 05: Global pharmaceutical market

Market size and forecast

PART 06: Road to pharmerging markets

PART 07: Pharmerging markets

PART 08: Market landscape

Medicine spending in emerging economies

Five forces analysis

PART 09: Market segmentation by geography

PART 10: Market overview of tier I countries


PART 11: Market overview of tier II countries




PART 12: Market overview of tier III countries

Market size and forecast

PART 13: Market drivers

Limitations in developed economies fuels demand in emerging economies

Increasing focus toward biosimilar in potential areas

Expansion initiatives of vendors

PART 14: Impact of drivers

PART 15: Market challenges

IP protection issues

Socio-political issues in cross geography transactions

Stringent price control and generic-centric usage lead to value erosion

PART 16: Impact of drivers and challenges

PART 17: Market trends

Potential of new countries in emerging markets

Positive outlook toward adoption of targeted therapies

Evolving stakeholder landscape to change market dynamics

PART 18: Vendor landscape

Competitive scenario

PART 19: Key vendor analysis






Other prominent vendors

PART 20: Appendix